Recently India’s drug regulator had given a green signal for the start of human clinical trials for the COVID-19 vaccine candidate Covaxin developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV). Soon after this on Saturday AIIMS Ethics Committee gave its approval for conducting the human clinical trial of the indigenously developed COVID-19 vaccine candidate Covaxin. Trials started on Monday. According to AIIMS director Dr Guleria Phase 1 vaccine trial will be conducted on healthy people aged 18-55 years who have no co-morbidity. The call for volunteers was received well by